Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PN401 with High Dose 5-FU vs Gemcitabine in Advanced Pancreatic Cancer
NCT00024427Phase 3Completed
- Sponsor
- Wellstat Therapeutics Corporation
- Start
- Feb 2001
- Primary completion
- Feb 2006
- Modality
- Nucleic Acid-Directed Small Molecules, Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 2
01
Overview
A Phase 3 trial of uridine triacetate in pancreatic cancer (PC), sponsored by Wellstat Therapeutics Corporation. Started Feb 2001; status: completed.
02
Drugs
uridine triacetate
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT00024427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00024427.